Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin

Hossein Aleyasin, Saravanan S. Karuppagounder, Amit Kumar, Sama Sleiman, Manuela Basso, Thong Ma, Ambreena Siddiq, Shankar J. Chinta, Camille Brochier, Brett Langley, Renee Haskew-Layton, Susan L. Bane, Gregory J. Riggins, Irina Gazaryan, Anatoly A. Starkov, Julie K. Andersen, Rajiv R. Ratan

Research output: Contribution to journalArticle

Abstract

Aims: Pharmacological activation of the adaptive response to hypoxia is a therapeutic strategy of growing interest for neurological conditions, including stroke, Huntington's disease, and Parkinson's disease. We screened a drug library with known safety in humans using a hippocampal neuroblast line expressing a reporter of hypoxia-inducible factor (HIF)-dependent transcription. Results: Our screen identified more than 40 compounds with the ability to induce hypoxia response element-driven luciferase activity as well or better than deferoxamine, a canonical activator of hypoxic adaptation. Among the chemical entities identified, the antihelminthic benzimidazoles represented one pharmacophore that appeared multiple times in our screen. Secondary assays confirmed that antihelminthics stabilized the transcriptional activator HIF-1α and induced expression of a known HIF target gene, p21cip1/waf1, in post-mitotic cortical neurons. The on-target effect of these agents in stimulating hypoxic signaling was binding to free tubulin. Moreover, antihelminthic benzimidazoles also abrogated oxidative stress-induced death in vitro, and this on-target effect also involves binding to free tubulin. Innovation and Conclusions: These studies demonstrate that tubulin-binding drugs can activate a component of the hypoxic adaptive response, specifically the stabilization of HIF-1α and its downstream targets. Tubulin-binding drugs, including antihelminthic benzimidazoles, also abrogate oxidative neuronal death in primary neurons. Given their safety in humans and known ability to penetrate into the central nervous system, antihelminthic benzimidazoles may be considered viable candidates for treating diseases associated with oxidative neuronal death, including stroke.

Original languageEnglish (US)
Pages (from-to)121-134
Number of pages14
JournalAntioxidants and Redox Signaling
Volume22
Issue number2
DOIs
StatePublished - Jan 10 2015

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology

Fingerprint Dive into the research topics of 'Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin'. Together they form a unique fingerprint.

  • Cite this

    Aleyasin, H., Karuppagounder, S. S., Kumar, A., Sleiman, S., Basso, M., Ma, T., Siddiq, A., Chinta, S. J., Brochier, C., Langley, B., Haskew-Layton, R., Bane, S. L., Riggins, G. J., Gazaryan, I., Starkov, A. A., Andersen, J. K., & Ratan, R. R. (2015). Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin. Antioxidants and Redox Signaling, 22(2), 121-134. https://doi.org/10.1089/ars.2013.5595